X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1053) 1053
Publication (123) 123
Book Review (12) 12
Conference Proceeding (5) 5
Book Chapter (3) 3
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (746) 746
sphingosine - analogs & derivatives (673) 673
fingolimod hydrochloride (671) 671
immunosuppressive agents - therapeutic use (665) 665
index medicus (656) 656
propylene glycols - therapeutic use (549) 549
animals (488) 488
multiple sclerosis (426) 426
male (416) 416
sphingosine - therapeutic use (415) 415
female (371) 371
fty720 (339) 339
fingolimod (334) 334
fingolimod hydrochloride - therapeutic use (303) 303
multiple sclerosis - drug therapy (282) 282
adult (252) 252
clinical neurology (252) 252
multiple sclerosis, relapsing-remitting - drug therapy (234) 234
mice (230) 230
oral fingolimod (229) 229
immunology (200) 200
propylene glycols - pharmacology (199) 199
middle aged (190) 190
rats (185) 185
immunosuppressive agents - pharmacology (178) 178
sphingosine - pharmacology (168) 168
neurosciences (166) 166
treatment outcome (162) 162
immunosuppressive agents - adverse effects (153) 153
transplantation (147) 147
neurology (140) 140
pharmacology & pharmacy (131) 131
sphingosine 1-phosphate (131) 131
surgery (126) 126
natalizumab (121) 121
disease models, animal (114) 114
analysis (106) 106
mice, inbred c57bl (106) 106
multiple-sclerosis (105) 105
drug therapy (101) 101
immunosuppressive agents - administration & dosage (97) 97
sphingosine (96) 96
sphingosine-1-phosphate (96) 96
propylene glycols - administration & dosage (95) 95
fingolimod hydrochloride - pharmacology (93) 93
interferon (93) 93
propylene glycols - adverse effects (93) 93
magnetic resonance imaging (92) 92
receptors, lysosphingolipid - metabolism (90) 90
research (89) 89
young adult (88) 88
fingolimod hydrochloride - adverse effects (86) 86
experimental autoimmune encephalomyelitis (85) 85
lymphocytes (85) 85
placebo-controlled trial (85) 85
abridged index medicus (84) 84
sphingosine - adverse effects (84) 84
relapsing multiple-sclerosis (80) 80
administration, oral (79) 79
sphingosine - administration & dosage (78) 78
immunologic factors - therapeutic use (77) 77
central-nervous-system (76) 76
care and treatment (75) 75
time factors (73) 73
multiple sclerosis - immunology (71) 71
graft survival - drug effects (70) 70
disease progression (69) 69
inflammation (69) 69
apoptosis (68) 68
immunosuppressant (68) 68
antibodies, monoclonal, humanized - therapeutic use (66) 66
article (65) 65
health aspects (65) 65
safety (65) 65
natalizumab - therapeutic use (64) 64
circulating mature lymphocytes (63) 63
interferon-beta - therapeutic use (62) 62
recurrence (62) 62
therapy (62) 62
phosphates (59) 59
dosage and administration (58) 58
double-blind (57) 57
research article (57) 57
adolescent (56) 56
drug therapy, combination (56) 56
hemic and lymphatic diseases (56) 56
lymphocyte egress (56) 56
t-cells (56) 56
rats, inbred lew (55) 55
sphingosine - metabolism (55) 55
medicine, general & internal (54) 54
patients (54) 54
dose-response relationship, drug (52) 52
glatiramer acetate (51) 51
medicine (51) 51
clinical trials as topic (49) 49
graft rejection - prevention & control (48) 48
in-vivo (48) 48
receptors, lysosphingolipid - agonists (48) 48
brain - pathology (47) 47
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (991) 991
Japanese (17) 17
German (9) 9
Spanish (9) 9
French (8) 8
Hungarian (7) 7
Chinese (5) 5
Russian (5) 5
Finnish (3) 3
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 4, pp. 691 - 715
Abstract Purpose Interferon injectables and glatiramer acetate have served as the primary disease-modifying treatments for multiple sclerosis (MS) since their... 
Internal Medicine | Medical Education | cost | disease-modifying treatments | multiple sclerosis | new drugs | pharmacotherapy | cost disease-modifying treatments multiple sclerosis new drugs pharmacotherapy | PEGYLATED INTERFERON BETA-1A | COST-EFFECTIVENESS | ORAL FINGOLIMOD FTY720 | PLACEBO-CONTROLLED PHASE-3 | INTRAMUSCULAR INTERFERON | CLINICAL-EFFICACY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | GLATIRAMER ACETATE | BG-12 DIMETHYL FUMARATE | QUALITY-OF-LIFE | United States | Humans | Immunosuppressive Agents - therapeutic use | Drug Approval | Polyethylene Glycols - economics | Polyethylene Glycols - therapeutic use | Interferon-beta - therapeutic use | Antibodies, Monoclonal, Humanized - economics | Dimethyl Fumarate - economics | Drug Costs - statistics & numerical data | Immunosuppressive Agents - economics | Fingolimod Hydrochloride - therapeutic use | Toluidines - economics | United States Food and Drug Administration | Fingolimod Hydrochloride - economics | Toluidines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Multiple Sclerosis - economics | Alemtuzumab | Interferon-beta - economics | Crotonates - therapeutic use | Crotonates - economics | Dimethyl Fumarate - therapeutic use | Glatiramer Acetate - therapeutic use | Glatiramer Acetate - economics | Multiple Sclerosis - drug therapy | Multiple sclerosis | Care and treatment | Biological response modifiers | Drug approval | Interferon | FDA approval | Drug therapy
Journal Article
Circulation, ISSN 0009-7322, 09/2015, Volume 132, Issue 12, pp. 1104 - 1112
Journal Article
Lancet Neurology, The, ISSN 1474-4422, 2017, Volume 16, Issue 4, pp. 271 - 281
Journal Article
Brain, ISSN 0006-8950, 11/2015, Volume 138, Issue 11, pp. 3275 - 3286
Journal Article
Circulation, ISSN 0009-7322, 03/2016, Volume 133, Issue 10, pp. 954 - 966
Journal Article